UPB (Upstream Bio) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Buildings And Improvements?

Upstream Bio Buildings And Improvements Historical Data

The historical data trend for Upstream Bio's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Buildings And Improvements Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Buildings And Improvements

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial			-	-	-	-	-

Upstream Bio Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.